非小细胞肺癌ERCC1表达与铂类药物疗效相关性的荟萃分析  

Meta-analysis of correlation between ERCC1 expression and efficacy of platinum-based chemotherapy in non-small cell lung cancer patients

作　　者：蒋倩[1] 蒋刚[1] 王怡鑫[1] 

机构地区：[1]四川省肿瘤医院药剂科,四川成都610041

出　　处：《中华肿瘤防治杂志》2012年第2期123-126,133,共5页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:运用循证医学的方法学原理,对中国非小细胞肺癌患者ERCC1表达与铂类药物疗效相关性进行评价,为肿瘤的个体化治疗提供一定的理论依据及策略。方法:检索2011-02前发表的中英文数据库,纳入中国人群ERCC1表达与基于铂类化疗方案疗效的临床对照研究。采用RevMan 4.2.8软件进行数据处理。结果:共纳入17项研究,累计病例1 293例,其中ERCC1阳性表达611例,ERCC1阴性表达682例。异质性检验显示,χ2=11.45,P=0.41;采用随机效应模型,合并OR值为2.82,95%CI:2.12～3.74,P<0.000 01。能接受纳入研究的偏倚,P=0.244。结论:ERCC1阴性表达与铂类药物化疗的疗效有很好的相关性。由于各研究报道的生存时间单位不统一无法合并,因此,对生存期的预测还不能完全确定。OBJECTIVE： To evaluate correlation between ERCC1 expression and efficacy of platinum-based chemotherapy in non-small cell lung cancer patients according to evidence-based medicine view,and provide evidence about individual treatment.METHODS： Chinese and English database was searched on cut-off Feb 2011,and controlled study about correlation among ERCC1 expression and efficacy of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer were included.Meta-analysis was conducted by the RevMan 4.2.8 software.RESULTS： Seventeen studies with 1 293 patients were identified,including 611 patients with ERCC1 positive expression and 682 with ERCC1 negative expression.There was no significantly statistical heterogeneity（χ2= 11.45,P=0.41）;random-effect pooled OR ratio was 2.82,95%CI was 2.12 to 3.74,and P0.000 01.No bias was detected（P=0.244）.CONCLUSIONS： ERCC1 negative expression can predict the curative efficacy of platinum-based chemotherapy.However,there is no sufficient evidence explaining whether it can predict survival time.

关 键 词：癌 非小细胞肺 铂类 DNA修复酶类 Meta分析 

分 类 号：R734.2[医药卫生—肿瘤]